62 related articles for article (PubMed ID: 24528044)
41. Current omics-based biomarkers for cholangiocarcinoma.
Intuyod K; Armartmuntree N; Jusakul A; Sakonsinsiri C; Thanan R; Pinlaor S
Expert Rev Mol Diagn; 2019 Nov; 19(11):997-1005. PubMed ID: 31566016
[No Abstract] [Full Text] [Related]
42. Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges.
Yang Y; Deng X; Li Q; Wang F; Miao L; Jiang Q
Cancer Commun (Lond); 2020 Dec; 40(12):655-680. PubMed ID: 33142045
[TBL] [Abstract][Full Text] [Related]
43. Circular RNA in cholangiocarcinoma: A systematic review and bibliometric analysis.
Zhou Z; Chen C; Han B; Wang Y; Liu Y; Liu Q; Xu X; Yin Y; Sun B
Pathol Res Pract; 2023 Sep; 249():154755. PubMed ID: 37651837
[TBL] [Abstract][Full Text] [Related]
44. BRCAness in biliary tract cancer: a new prognostic and predictive biomarker?
Hachem S; Kassis Y; Hachem MC; Zouein J; Gharios J; Kourie HR
Biomark Med; 2023 Jan; 17(1):51-57. PubMed ID: 36994675
[TBL] [Abstract][Full Text] [Related]
45. The Role of Single-Nucleotide Polymorphisms in Cholangiocarcinoma: A Systematic Review.
Wang G; Heij LR; Liu D; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497451
[TBL] [Abstract][Full Text] [Related]
46. Understanding the genetic basis for cholangiocarcinoma.
Schmidt MA; Roberts LR
Adv Cancer Res; 2022; 156():137-165. PubMed ID: 35961698
[TBL] [Abstract][Full Text] [Related]
47. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
Simile MM; Bagella P; Vidili G; Spanu A; Manetti R; Seddaiu MA; Babudieri S; Madeddu G; Serra PA; Altana M; Paliogiannis P
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30743998
[TBL] [Abstract][Full Text] [Related]
48. Genetic and environmental determinants of risk for cholangiocarcinoma in Thailand.
Miwa M; Honjo S; You G; Tanaka M; Uchida K; Srivatanakul P; Khuhaprema T; Loilome W; Techasen A; Wongkham C; Limpaiboon T; Yongvanit P; Wongkham S
World J Gastrointest Pathophysiol; 2014 Nov; 5(4):570-8. PubMed ID: 25401000
[TBL] [Abstract][Full Text] [Related]
49. Genomic structure and variation of nuclear factor (erythroid-derived 2)-like 2.
Cho HY
Oxid Med Cell Longev; 2013; 2013():286524. PubMed ID: 23936606
[TBL] [Abstract][Full Text] [Related]
50. Genetic polymorphism in the NRF2 gene as a prognosis marker for cancer chemotherapy.
Ishikawa T
Front Genet; 2014; 5():383. PubMed ID: 25408701
[TBL] [Abstract][Full Text] [Related]
51. The significance of genetics for cholangiocarcinoma development.
Maroni L; Pierantonelli I; Banales JM; Benedetti A; Marzioni M
Ann Transl Med; 2013 Oct; 1(3):28. PubMed ID: 25332972
[TBL] [Abstract][Full Text] [Related]
52. Cholangiocarcinoma: a guide for the nonspecialist.
Alsaleh M; Leftley Z; Barbera TA; Sithithaworn P; Khuntikeo N; Loilome W; Yongvanit P; Cox IJ; Chamodol N; Syms RR; Andrews RH; Taylor-Robinson SD
Int J Gen Med; 2019; 12():13-23. PubMed ID: 30588065
[TBL] [Abstract][Full Text] [Related]
53. Current Advances in Basic and Translational Research of Cholangiocarcinoma.
Sato K; Baiocchi L; Kennedy L; Zhang W; Ekser B; Glaser S; Francis H; Alpini G
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282753
[TBL] [Abstract][Full Text] [Related]
54. An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.
Seeree P; Pearngam P; Kumkate S; Janvilisri T
Int J Genomics; 2015; 2015():179528. PubMed ID: 26421274
[TBL] [Abstract][Full Text] [Related]
55.
Zhao S; Xu Y; Wu W; Wang P; Wang Y; Jiang H; Zhu J
Front Oncol; 2021; 11():693295. PubMed ID: 34249744
[TBL] [Abstract][Full Text] [Related]
56. Selecting an Appropriate Experimental Animal Model for Cholangiocarcinoma Research.
Li M; Zhou X; Wang W; Ji B; Shao Y; Du Q; Yao J; Yang Y
J Clin Transl Hepatol; 2022 Aug; 10(4):700-710. PubMed ID: 36062286
[TBL] [Abstract][Full Text] [Related]
57. Association of NRF2 polymorphism with cholangiocarcinoma prognosis in Thai patients.
Khunluck T; Kukongviriyapan V; Puapairoj A; Khuntikeo N; Senggunprai L; Zeekpudsa P; Prawan A
Asian Pac J Cancer Prev; 2014; 15(1):299-304. PubMed ID: 24528044
[TBL] [Abstract][Full Text] [Related]
58. Genomic and transcriptional alterations of cholangiocarcinoma.
Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
[TBL] [Abstract][Full Text] [Related]
59. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
Golan T; Raitses-Gurevich M; Kelley RK; Bocobo AG; Borgida A; Shroff RT; Holter S; Gallinger S; Ahn DH; Aderka D; Apurva J; Bekaii-Saab T; Friedman E; Javle M
Oncologist; 2017 Jul; 22(7):804-810. PubMed ID: 28487467
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
